Carbapenem-Resistant Enterobacteriaceae Infection Clinical Trial
Official title:
Ceftazidime-Avibactam Versus Colistin in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections (AVI-ICU): A Non-Inferiority Randomized Clinical Trial
Carbapenem-Resistant Enterobacteriaceae (CRE) infections are a growing national and international challenge in healthcare settings. This is not only due to the rapid spread of resistance and paucity of options of targeted-antimicrobial agents, but also owing to the high mortality of patients infected with CRE reaching up to 50% as per the Centers of Disease Control and Prevention. Colistin-based combination regimens have been the mainstay for treating CRE-related infections. Ceftazidime-avibactam is a beta-lactamase inhibitor combination, a novel antibiotic, which recently showed a better clinical and microbiological cure against CRE along with the potential to reduce mortality and nephrotoxicity in comparison to colistin-based regimens in observational studies. However, randomized clinical trials are lacking. This non-inferiority randomized controlled study aims to assess the efficacy and safety of ceftazidime-avibactam-based regimens in critically ill patients with CRE infections in comparison to colistin-based regimens.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06051513 -
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
|
N/A | |
| Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
| Completed |
NCT04146337 -
Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae
|
Phase 2/Phase 3 | |
| Completed |
NCT04167228 -
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria
|
||
| Terminated |
NCT04876430 -
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
|
Phase 2/Phase 3 | |
| Enrolling by invitation |
NCT03924934 -
Community-associated Highly-Resistant Enterobacterales
|
||
| Recruiting |
NCT04583098 -
The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
|
||
| Recruiting |
NCT04535661 -
Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
|
||
| Withdrawn |
NCT04785924 -
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
|
Phase 4 | |
| Not yet recruiting |
NCT04746222 -
Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04014413 -
Safety and Efficacy of Fecal Microbiota Transplantation
|
N/A | |
| Recruiting |
NCT05871476 -
Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals
|
N/A | |
| Recruiting |
NCT05850871 -
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
|
N/A | |
| Terminated |
NCT05210387 -
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
|
N/A | |
| Not yet recruiting |
NCT06210542 -
Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
|
||
| Not yet recruiting |
NCT05981430 -
Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae
|
N/A | |
| Recruiting |
NCT06258551 -
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
|
||
| Recruiting |
NCT05979545 -
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
|
Phase 4 | |
| Completed |
NCT04790565 -
Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae
|
Phase 2/Phase 3 |